Phase II
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Akari Therapeutics, plc announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).
Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced an oral presentation will be given at the 28th EADV Congress.
Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced that the first patient has been randomized in its “TRAVERS” Phase 2 trial of AM-125, the Company’s investigational drug for the treatment of acute vertigo.
PRESS RELEASES